DEC 01, 2021 7:07 AM PST

Is GDF-15 a Valuable Biomarker for Congestive Heart Failure?

Congestive Heart Failure (CHF) is a serious medical condition that results in the heart not being able to pump to meet the body's demands successfully. CHF is generally caused by long-standing chronic diseases such as diabetes, high blood pressure, and ischemic heart disease. Notably, it is associated with significant mortality and consumption of healthcare resources. Between 2000 and 2010, it was estimated that 1 million hospitalizations were related to CHF in the United States. Due to the serious nature of CHF, it is necessary to have a reliable biomarker to estimate the outcome of this disease. Traditionally laboratory markers such as B-type Natriuretic Peptide (BNP) have been used to diagnose and predict outcomes in heart failure. Although valuable, BNP is impacted by other factors such as age and certain medical conditions, limiting its clinical usefulness.

Previous animal studies have demonstrated that Growth Differentiation Factor-15 (GDF-15) is upregulated in response to cardiac stress. Certain studies have also indicated that levels are higher in human patients with CHF. As such, investigators have performed a meta-analysis to determine whether GDF-15 can serve as a reliable biomarker in the prognostic evaluation of CHF.

The meta-analysis included ten studies with over 6 thousand participants. Rigorous bias assessment was performed, and publication bias was controlled using various methods. In addition, all included studies were deemed high quality based on Newcastle-Ottawa-Scale methodology. Results indicated that all-cause mortality significantly increased with increasing levels of GDF-15 in patients with ischemic CHF. The risk of death was also more strongly associated with patients that had CHF with reduced ejection fraction. Limitations of this analysis include heterogeneity across eligible studies, possibly due in part to factors such as comorbidities among study participants and different assay methods for measuring GDF-15. 

This evidence strongly suggests that GDF-15 may serve as a useful biomarker in the prognostication of CHF. Further studies should focus on factors such as GDF-15 levels for stratifying patients into different risk categories. In addition, the impact of age and medical comorbidities on the prognostic utility of GDF-15 should also be evaluated. 

 

 

Sources: CDC, Circulation Research, Frontiers in Cardiovascular Medicine

About the Author
  • Dr. Christopher DiMaio is a Science Writer at Labroots. He received his MD from Penn State College of Medicine in 2014. His academic and professional interests include Neuroscience, Behavioral health, Immunology, and Healthcare improvement, among others. He is an active part of his community.
You May Also Like
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
SEP 28, 2021
Drug Discovery & Development
The FDA approves drug to treat a bad cholesterol in children
SEP 28, 2021
The FDA approves drug to treat a bad cholesterol in children
Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, whi ...
DEC 14, 2021
Clinical & Molecular DX
Bacterial Communities Change Dramatically as Gum Disease Worsens
DEC 14, 2021
Bacterial Communities Change Dramatically as Gum Disease Worsens
Researchers have mapped bacterial signatures that differentiate healthy gums from those with gingivitis and periodontiti ...
JAN 04, 2022
Health & Medicine
Study Shows Young Newlyweds Match in Cardiovascular Risk Factors
JAN 04, 2022
Study Shows Young Newlyweds Match in Cardiovascular Risk Factors
Ever heard of the matching hypothesis? It's where people who look alike tend to pair off into couples. Well, now sci ...
JAN 18, 2022
Cardiology
New Study Links Mental Stress to Cardiovascular Disease
JAN 18, 2022
New Study Links Mental Stress to Cardiovascular Disease
We all know stress is bad for us. A new study confirms that psychological stress leads to greater risk for our hearts.
JAN 27, 2022
Drug Discovery & Development
The way to the heart is through the toilet seat. Casana raises $30million for its blood pressure monitoring toilet seat.
JAN 27, 2022
The way to the heart is through the toilet seat. Casana raises $30million for its blood pressure monitoring toilet seat.
Casana, a healthcare company based out of Rochester, New York, announced early this week that it has raised $3 ...
Loading Comments...